Aggressive Therapie der tiefen Venenthrombose – Kontra

Zusammenfassung

Neben der klassischen konservativen Therapie und der selten notwendigen chirurgischen Therapie werden kathetergestützte Lyseverfahren zunehmend häufiger in der Therapie der akuten tiefen Venenthrombose eingesetzt. Unser Reviewartikel beleuchtet die Datenlage zu diesem Verfahren kritisch und ist als „Kontra“-Standpunkt, als Gegenüberstellung zum ebenfalls in diesem Heft erscheinenden „Pro“-Artikel zu verstehen.

Abstract

Together with the classical conservative treatment or the rarely necessary surgical thrombectomy in patients with acute deep vein thrombosis, catheter-directed thrombolysis is becoming more and more popular. This review provides a critical view on the evidence for catheter-directed thrombolysis providing a “Contra” position in contrast to the “Pro” position also published in this issue.

Schlüsselwörter

Antikoagulation - endovaskuläre Therapie - tiefe Venenthrombose - Ulcus cruris

Key words

anticoagulation - endovascular treatment - deep vein thrombosis - venous ulcer

• Literatur

• 1 Naess IA, Christiansen SC, Romundstad P et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5: 692-699
• 2 Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008; 28: 370-372
• 3 White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: 4-8
• 4 Wells PS, Forster AJ. Thrombolysis in deep vein thrombosis: is there still an indication?. Thromb Haemost 2001; 86: 499-508
• 5 Goldhaber SZ, Hirsch DR, MacDougall RC et al. Bolus recombinant urokinase versus heparin in deep venous thrombosis: a randomized controlled trial. Am Heart J 1996; 132: 314-318
• 6 Kiil J, Carvalho A, Sakso P et al. Urokinase or heparin in the management of patients with deep vein thrombosis?. Acta Chir Scand 1981; 147: 529-532
• 7 Schwieder G, Grimm W, Siemens HJ et al. Intermittent regional therapy with rt-PA is not superior to systemic thrombolysis in deep vein thrombosis (DVT)–a German multicenter trial. Thromb Haemost 1995; 74: 1240-1243
• 8 Watson LI, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev 2004; (4) CD002783
• 9 Buller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) S401-S428
• 10 Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e419S-494S
• 11 Gogalniceanu P, Johnston CJ, Khalid U et al. Indications for thrombolysis in deep venous thrombosis. Eur J Vasc Endovasc Surg 2009; 38: 192-198
• 12 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900
• 13 Le Gal G, Carrier M, Kovacs MJ et al. Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study. J Thromb Haemost 2011; 9: 1126-1132
• 14 Kahn SR. Post-thrombotic syndrome after deep venous thrombosis: risk factors, prevention, and therapeutic options. Clin Adv Hematol Oncol 2009; 7: 433-435
• 15 Prandoni P, Lensing AW, Prins MH et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004; 141: 249-256
• 16 Lindner DJ, Edwards JM, Phinney ES et al. Long-term hemodynamic and clinical sequelae of lower extremity deep vein thrombosis. J Vasc Surg 1986; 4: 436-442
• 17 Strandness Jr. DE, Langlois Y, Cramer M et al. Long-term sequelae of acute venous thrombosis. JAMA 1983; 250: 1289-1292
• 18 Kahn SR, Ginsberg JS. The post-thrombotic syndrome: current knowledge, controversies, and directions for future research. Blood Rev 2002; 16: 155-165
• 19 Brandjes DPM, Büller HR, Heijboer H et al. Randomized trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759-762
• 20 Parikh S, Motarjeme A, McNamara T et al. Ultrasound-accelerated thrombolysis for the treatment of deep vein thrombosis: initial clinical experience. J Vasc Interv Radiol 2008; 19: 521-528
• 21 Lin PH, Zhou W, Dardik A et al. Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis. Am J Surg 2006; 192: 782-788
• 22 Elsharawy M, Elzayat E. Early results of thrombolysis vs. anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial. Eur J Vasc Endovasc Surg 2002; 24: 209-214
• 23 AbuRahma AF, Perkins SE, Wulu JT et al. Iliofemoral deep vein thrombosis: conventional therapy versus lysis and percutaneous transluminal angioplasty and stenting. Ann Surg 2001; 233: 752-760
• 24 Sharifi M, Mehdipour M, Bay C et al. Endovenous therapy for deep venous thrombosis: the TORPEDO trial. Catheter Cardiovasc Interv 2010; 76: 316-325
• 25 Enden T, Haig Y, Klow NE et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379: 31-38
• 26 Comerota AJ, Grewal N, Martinez JT et al. Postthrombotic morbidity correlates with residual thrombus following catheter-directed thrombolysis for iliofemoral deep vein thrombosis. J Vasc Surg 2012; 55: 768-773
• 27 Agnelli G, Gallus A, Goldhaber SZ et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116: 180-187
• 28 Agnelli G, Verso M, Ageno W et al. The MASTER registry on venous thromboembolism: description of the study cohort. Thromb Res 2008; 121: 605-610
• 29 Ruiz-Gimenez N, Suarez C, Gonzalez R et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 26-31
• 30 Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808
• 31 Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510
• 32 Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352
• 33 Buller HR, Decousus H, Grosso MA et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415
• 34 Donadini MP, Ageno W, Antonucci E et al. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis. A patient-level meta-analysis. Thromb Haemost 2014; 111: 172-179
• 35 Baldwin MJ, Moore HM, Rudarakanchana N et al. Post-thrombotic syndrome: a clinical review. J Thromb Haemost 2013; 11: 795-805
• 36 Soosainathan A, Moore HM, Gohel MS et al. Scoring systems for the post-thrombotic syndrome. J Vasc Surg 2013; 57: 254-261
• 37 Schwarz T, Schmidt B, Beyer J et al. Eligibility for home treatment of deep vein thrombosis: a prospective study in 202 consecutive patients. J Vasc Surg 2001; 34: 1065-1070
• 38 Schwarz T, Schmidt B, Hohlein U et al. Eligibility for home treatment of deep vein thrombosis: prospective study. BMJ 2001; 322: 1212-1213
• 39 Hach-Wunderle V. Diagnostik und Therapie der Venenthrombose und der Lungenembolie. AWMF-Leitlinienregister 065/002 2010. Im Internet: http://www.awmf.org/leitlinien/detail/ll/065-002.html Stand: 04. 01. 2014